Germany-based molecular diagnostics technology developer GNA Biosolutions has completed a $13.5m series C round backed by industrial product manufacturer Robert Bosch’s corporate venturing arm, Robert Bosch Venture Capital (RBVC).
The round included GreyBird Ventures, Occident, Wachstumsfonds Bayern, SHS Gesellschaft für Beteiligungsmanagement, UVC Partners, Mey Capital Matrix, KfW and Btov Partners, while Greybird partner Tom Miller has been appointed chairman of GNA.
GNA provides technology used by clinical laboratories to detect infectious diseases. Its platform provides molecular diagnostic by leveraging Pulse Controlled Amplification technology, which captures nucleic acids from clinical samples.
RBVC previously led the company’s $6.6m series B round in 2015, investing alongside KfW, SHS Gesellschaft für Beteiligungsmanagement, Btov Partners, Mey Capital Matrix and UnternehmerTUM, the tech transfer office of Technical University of Munich that is affiliated with UVC Partners.
Mey Capital Matrix and KfW were existing investors prior to the series B round, though GNA has not revealed details of their funding. The company was formed as a spinout of public research university Ludwig-Maximilians-Universität.